Recursion Pharmaceuticals
RXRX
RXRX
198 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 70 increasing their positions, 48 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
24% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 34
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
3% more funds holding
Funds holding: 192 → 198 (+6)
Holders
198
Holding in Top 10
6
Calls
$8.93M
Puts
$4.34M
Top Buyers
| 1 | +$136M | |
| 2 | +$56M | |
| 3 | +$55.9M | |
| 4 |
Morgan Stanley
New York
|
+$42.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.1M |
Top Sellers
| 1 | -$8.01M | |
| 2 | -$5.66M | |
| 3 | -$5.04M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
-$4.24M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$3.67M |